Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Lonazolac
Cat. No.:
0225LY-0868
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by LC-MS.
Size:
Add to basket
Product Overview
Description:
Lonazolac is a pharmaceutical agent classified as a nonsteroidal anti-inflammatory drug (NSAID).
Synonym:
53808-88-1; Lonazolacum; [3-(4-Chlorophenyl)-1-phenyl-1H-pyrazol-4-yl]acetic acid; 2-(3-(4-Chlorophenyl)-1-phenyl-1H-pyrazol-4-yl)acetic acid; 3-(p-Chlorophenyl)-1-phenylpyrazole-4-acetic acid; 2-[3-(4-chlorophenyl)-1-phenylpyrazol-4-yl]acetic acid; 1H-Pyrazole-4-acetic acid, 3-(4-chlorophenyl)-1-phenyl-; 2-[3-(4-chlorophenyl)-1-phenyl-1H-pyrazol-4-yl]acetic acid; Lonazolac calcium salt
CAS No.:
53808-88-1
Compound CID:
68706
Formula:
C17H13ClN2O2
Formula Weight:
312.75
Specification
Relative Density:
1.3 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Lonazolac can be used in inflammation research to study the non-selective inhibition of cyclooxygenase enzymes.
Library Information
Target:
PPAR
Receptor:
PPARγ
Pathways:
Metabolism; DNA damage/DNA repair
Plate Number:
AOCL-12
Plate Location:
b7
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
50 mg/mL; 159.87 mM
